Table 3 |
|||||||
| Outcome measures, assessment methods, and assessment time points of the study | |||||||
| Measures | Assessment methods | 1. Test 1 Day Pre-OP | 2. Test 6-12 Wk. Post-OP | 3. Test 6 Mo. Post-OP (only IG) | 4. Test 9 Mo. Post-OP (only IG) | 5. Test 12. Mo. Post-OP (only IG) | 6. Test 18. Mo. Post-OP |
| 15-month exercise intervention | |||||||
| Physical performance | Spiroergometry on treadmill | x | x | x | |||
| Incontinence | Pad-Test | x | x | x | |||
| PSA, Testosterone, Endostatin, VEGF | Blood Sample | x | x | x | |||
| Quality of Life | EORTC-QLQ-C30/PR 25 | x | x | x | x | x | x |
| Erectile Dysfunction | IIEF – Questionnaire | x | x | x | x | x | x |
| Physical Activity Level (MET- Score) | Freiburger Questionnaire of Physical Activity | x | x | x | x | x | |
| Compliance | Compliance Questionnaire | x | x | x | x | x | |
EORTC-QLQ-C30/PR25: European Organization for Research and Treatment of Cancer- Quality of Life Questionnaire- Cancer/Prostate Cancer Module, IG: intervention group, IIEF: International Index of Erectile Function, MET: metabolic equivalent, Post-OP: after surgery/primary treatment, Pre-OP: prior to surgery/primary treatment, PSA: prostate-specific antigen, VEGF: vascular endothelial growth factor.
Zopf et al. BMC Cancer 2012 12:312 doi:10.1186/1471-2407-12-312
